Celldex Therapeutics (CLDX) EBITDA Margin (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly EBITDA Margin of 562900.0% for Q1 2026, down 55387281.0% year-over-year from N/an in Q1 2025, and down 681.51% quarter-over-quarter from 72027.27% in Q4 2025.
Celldex Therapeutics (CLDX) EBITDA Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBITDA Margin history runs 17 years deep, the most recent figure standing at 562900.0% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 55387281.0% year-over-year to 562900.0%; the TTM figure through Mar 2026 stood at 35688.45% (down 3281494.0% YoY), while the FY2025 annual figure was 18599.81%, down 1582092.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 562900.0%, down from 72027.27% in the prior quarter.
- The five-year high for EBITDA Margin was 1152.92% in Q4 2023, with the low at 562900.0% in Q1 2026.
- The 5-year median for EBITDA Margin is 7776.22% (2022), against an average of 46927.28%.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin jumped 1700357 bps in 2025, then plunged 55387281 bps in 2026.
- Celldex Therapeutics' EBITDA Margin stood at 1728.77% in 2022, then soared by 33 bps to 1152.92% in 2023, then slumped by 314 bps to 4768.26% in 2024, then slumped by 1411 bps to 72027.27% in 2025, then sank by 682 bps to 562900.0% in 2026.
- Business Quant data shows CLDX's EBITDA Margin at 562900.0% in Q1 2026, 72027.27% in Q4 2025, and 8747.53% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -366,468.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -366,468.18% |
| Mar 31, 2026 | -562,900.00% |
| Dec 31, 2025 | -72,027.27% |
| Jun 30, 2025 | -8,747.53% |
| Mar 31, 2025 | -9,027.19% |
| Dec 31, 2024 | -4,768.26% |
| Sep 30, 2024 | -1,633.53% |
| Jun 30, 2024 | -1,854.16% |
| Mar 31, 2024 | -26,030.77% |
| Dec 31, 2023 | -1,152.92% |
| Sep 30, 2023 | -2,718.46% |
| Jun 30, 2023 | -12,389.93% |
| Mar 31, 2023 | -3,357.91% |
| Dec 31, 2022 | -1,728.77% |
| Sep 30, 2022 | -6,804.91% |
| Jun 30, 2022 | -22,328.83% |
| Mar 31, 2022 | -13,366.09% |
| Dec 31, 2021 | -6,089.82% |
| Sep 30, 2021 | -13,610.46% |
| Jun 30, 2021 | -386.21% |